Thus, these results are consistent with our observation that homozygous carriers of MS-associated IL2RA risk allele rs2104286 and rs11256593 have decreased MFI of CD25 on TReg cells with an EM phenotype or CD39+ and CD4+CD127+CD25+ T cell subsets being CD45RA−/lo or expressing CXCR3 and/or CCR6, markers preferentially expressed on memory CD4+ T cells [49]. This evidence concerns the gene IL2RA and myeloid sarcoma.